

EV Biologics Announces Cessation of Trading and Wind-Up of Business Operations

Company Confirms No Remaining Assets and Closure of Corporate Bank Account

January 30, 2025

TAMPA, FL – January 15, 2025 – EV Biologics Corp. (OTC PINK: YECO)

EV Biologics today announced that, effective January 30, 2025, at the market close, the Company has ceased all trading activities and is formally winding up its business operations.

After a comprehensive review of its financial position and strategic options, the Company determined that it no longer maintains operational capacity or viable assets to continue business activities. As part of the wind-up process, EV Biologics confirms that it holds no remaining assets and that its corporate bank account was closed in 2025.

The decision follows the full cessation of research, development, and commercial initiatives previously undertaken by the Company. All business activities have been discontinued, and the Company is proceeding with administrative steps required to conclude and terminate all corporate matters.

EV Biologics does not anticipate any future operations, financings, or commercial programs. This announcement serves as formal public notice of the Company's closure.

"considers" or similar expressions are intended to identify "forward-looking statements." EV Biologics was a biotechnology focused company engaged in the exploration of extracellular vesicle and regenerative medicine-related technologies. The Company is no longer conducting operations.

Forward-Looking Statements

This news release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will

continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

This press release contains statements regarding the wind-up and closure of EV Biologics. These statements reflect the Company's current status and intentions as of the date of this release. No obligation is undertaken to update any information contained herein.